F19.97 Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia

Name of the Condition

• Other Psychoactive Substance Use, Unspecified with Psychoactive Substance-Induced Persisting Dementia
• ICD-10 Code: F19.97

Summary

This condition involves the use of a psychoactive substance not classified under more specific categories (e.g., alcohol, cannabis, opioids) where the substance is unidentified, and it is associated with persisting dementia. The "unspecified" designation applies when the exact agent is unknown or not documented, while "with psychoactive substance-induced persisting dementia" indicates a chronic cognitive impairment resulting from substance use.

Causes

The condition may result from experimentation, recreational use, or habitual consumption of various psychoactive substances. These substances can alter perception, mood, cognition, or behavior, though the specific agent is not specified. Persisting dementia occurs when substance-related brain changes lead to lasting cognitive deficits.

Risk Factors

• Peer pressure or cultural acceptance of substance use.
• Stressful life circumstances or co-occurring mental health conditions (e.g., anxiety, depression).
• Availability of and access to psychoactive substances.
• Prolonged or high-dose use of unidentified psychoactive agents.

Symptoms

Symptoms vary based on the substance but may include altered perception, mood swings, impaired judgment, or changes in behavior. Dementia-specific symptoms can include memory loss, difficulty with language or problem-solving, and impaired daily functioning. The exact presentation depends on the unidentified psychoactive agent.

Diagnosis

Diagnosis typically involves a clinical assessment, including patient history and behavioral observations. Lab tests may be used if the substance identity is unknown, though no specific tests are standard. Neurological or cognitive evaluations help confirm persisting dementia, and substance use history is critical to link the condition to psychoactive substance exposure.

Treatment Options

• Counseling and Behavioral Therapies: Aim to modify substance use behaviors and address cognitive impairments.
• Support Groups: Provide community and resources for ongoing recovery.
• Medication Management: May include drugs to manage symptoms or co-occurring conditions.
• Cognitive Rehabilitation: Focuses on improving memory, attention, and daily functioning.

Prognosis and Follow-Up

Prognosis depends on the extent of cognitive damage and the ability to discontinue substance use. Early intervention may slow progression, but some deficits may be permanent. Regular follow-up with healthcare providers is essential to monitor cognitive status and adjust treatment as needed.

Complications

• Worsening cognitive decline or permanent brain damage.
• Increased risk of accidents or injuries due to impaired judgment.
• Social isolation or difficulty maintaining relationships.
• Higher likelihood of co-occurring mental health disorders.

Lifestyle & Prevention

• Avoiding unidentified psychoactive substances.
• Seeking help for substance use concerns early.
• Engaging in cognitive-stimulating activities to support brain health.
• Maintaining a stable, supportive environment to reduce relapse risk.

When to Seek Professional Help

Seek care if you or someone you know experiences persistent memory loss, confusion, or changes in behavior after substance use, or if substance use is interfering with daily life. Immediate medical attention is needed for severe cognitive impairment or safety concerns.

Tips for Medical Coders

Document the presence of persisting dementia and its link to psychoactive substance use. Ensure the substance is unspecified (not identified) and that dementia is directly attributed to the substance, not another cause. Include details on cognitive impairment and substance use history to support accurate coding.